Every material Form 8-K Krystal Biotech filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Krystal Biotech reported third quarter 2026 net product revenue of $127.3 million for VYJUVEK and net income of $63.1 million, compared to $79.4 million in the prior year period. The company also announced that its board of directors authorized a share repurchase program of up to $400 million.
Third quarter 2026 net product revenue for VYJUVEK was $127.3 million, up 30% year-over-year.
Net income for the third quarter of 2026 was $63.1 million, or $2.05 per diluted share.
Cash, cash equivalents, and investments totaled $1.2 billion as of September 30, 2026.
The board authorized a share repurchase program of up to $400 million.
Krystal Biotech reported second quarter 2026 results on August 3, 2026. VYJUVEK net product revenue rose 24% from the prior year quarter to $119.2 million, and net income was $54.8 million, or $1.79 per diluted share, versus $38.3 million a year earlier. The company also gave full-year 2026 non-GAAP R&D and SG&A expense guidance of $175.0 million to $195.0 million.
Q2 2026 product revenue, net was $119.2 million, up from $96.0 million in Q2 2025
Q2 2026 net income was $54.8 million, or $1.79 per diluted share, versus $1.29 a year earlier
First-half 2026 product revenue was $235.6 million, up from $184.2 million; cash and investments totaled $1.1 billion at June 30, 2026
FY 2026 non-GAAP R&D and SG&A expense guidance is $175.0 million to $195.0 million, excluding stock-based compensation
Krystal Biotech reported fourth-quarter and full-year 2025 results, with product revenue from VYJUVEK rising from the prior-year periods. Net income for the quarter was $51.4 million, or $1.70 per diluted share, compared with $45.5 million, or $1.52 per diluted share, a year earlier. The company also issued fiscal 2026 non-GAAP R&D and SG&A expense guidance of $175.0 million to $195.0 million.
Q4 2025 product revenue, net, was $107.1 million, up from $91.1 million in Q4 2024.
Full-year 2025 product revenue, net, was $389.1 million, up from $290.5 million in 2024.
Full-year 2025 net income was $204.8 million, or $6.84 per diluted share, versus $89.2 million, or $3.00 per diluted share, in 2024.
FY 2026 non-GAAP R&D and SG&A expense guidance is $175.0 million to $195.0 million, excluding stock-based compensation.
Krystal Biotech disclosed preliminary, unaudited 2025 results ahead of its J.P. Morgan Healthcare Conference presentation on January 12, 2026, including VYJUVEK net product revenue and cash of about $955 million as of December 31, 2025. It also gave 2026 combined non-GAAP R&D and SG&A expense guidance of $175 million to $195 million. The company said its audit is ongoing and the figures could change, with full 2025 results due in February 2026.
Preliminary Q4 2025 VYJUVEK net product revenue of $106 million to $107 million; full year 2025 of $388 million to $389 million
Cash, cash equivalents and investments of approximately $955 million as of December 31, 2025
2026 combined non-GAAP R&D and SG&A expense guidance of $175 million to $195 million, excluding stock-based compensation
Figures are unaudited and subject to change; full 2025 results to be reported in February 2026
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Krystal Biotech filing is on SEC EDGAR ↗. 8-K briefs of other companies →